Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
59,112,975
-
Total 13F shares
-
32,181,067
-
Share change
-
-5,496,655
-
Total reported value
-
$329,206,034
-
Put/Call ratio
-
54%
-
Price per share
-
$10.23
-
Number of holders
-
96
-
Value change
-
-$56,391,053
-
Number of buys
-
46
-
Number of sells
-
45
Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock (CGEM) as of Q1 2023
As of 31 Mar 2023,
Cullinan Therapeutics, Inc. - Common Stock (CGEM) was held by
96 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
32,181,067 shares.
The largest 10 holders included
BIOIMPACT CAPITAL LLC, CHI Advisors LLC, BVF INC/IL, VANGUARD GROUP INC, BlackRock Inc., AMERICAN INTERNATIONAL GROUP, INC., Nextech Invest Ltd., Boxer Capital, LLC, FRANKLIN RESOURCES INC, and Rubric Capital Management LP.
This page lists
96
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.